Novavax announced that the European Commission granted Marketing Authorization for Novavax’s updated 2024-2025 Nuvaxovid COVID-19 Vaccine, dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union. This decision follows the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Biotech Alert: Searches spiking for these stocks today
- Novavax clarifies ‘has neither updated nor reaffirmed’ FY24 financial guidance
- Morning Movers: Hims & Hers sinks after FDA calls tirzepatide shortage over
- Levi Strauss mulls Dockers strategic alternatives: Morning Buzz
- Novavax Comments on Expected U.S. Vaccine Market Outlook